A share price of SpringWorks Therapeutics Inc [SWTX] is currently trading at $57.43, down -1.98%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SWTX shares have gain 42.58% over the last week, with a monthly amount glided 71.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SpringWorks Therapeutics Inc [NASDAQ: SWTX] stock has seen the most recent analyst activity on November 20, 2024, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $60. Previously, Guggenheim started tracking the stock with Buy rating on February 05, 2024, and set its price target to $75. On December 01, 2022, BofA Securities initiated with a Buy rating and assigned a price target of $45 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $101 on January 19, 2021. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $73 on October 29, 2020. Barclays started tracking with a Overweight rating for this stock on May 05, 2020, and assigned it a price target of $48. In a note dated March 19, 2020, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $40 to $60.
SpringWorks Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $28.21 and $60.00. Currently, Wall Street analysts expect the stock to reach $78 within the next 12 months. SpringWorks Therapeutics Inc [NASDAQ: SWTX] shares were valued at $57.43 at the most recent close of the market. An investor can expect a potential return of 35.82% based on the average SWTX price forecast.
Analyzing the SWTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -2.18%, Pretax Profit Margin comes in at -2.03%, and Net Profit Margin reading is -2.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.48 and Total Capital is -0.55. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 56.47 points at the first support level, and at 55.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 59.20, and for the 2nd resistance point, it is at 60.96.
Ratios To Look Out For
To put it in perspective, the Current Ratio for SpringWorks Therapeutics Inc [NASDAQ:SWTX] is 6.16. Further, the Quick Ratio stands at 6.02, while the Cash Ratio is 1.2. Considering the valuation of this stock, the price to sales ratio is 31.53, the price to book ratio is 8.02.
Transactions by insiders
Recent insider trading involved DANIEL LYNCH, Director, that happened on Feb 14 ’25 when 48000.0 shares were purchased. Chief People Officer, Pichl Daniel completed a deal on Feb 10 ’25 to sell 29750.0 shares. Meanwhile, Director LYNCH DANIEL sold 0.17 million shares on Feb 10 ’25.
